IL18 and diffuse large B-cell lymphoma: The impact of pretreatment IL-18 serum levels on the outcome of DLBCL patients receiving Rituximab-CHOP was investigated by Khaled et al. The authors reported that CR and 3-year disease-free survival (DFS) rates were lower for patients with increased IL-18 serum levels, though the difference was not statistically significant.